Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
August 5, 2021 7:30 AM EDTToday Announced Agreement with Roche to Evaluate SY-5609 in Combination with Immunotherapy in BRAF-Mutant Colorectal Cancer Patients
Additional Dose Escalation Data for SY-5609 to be Highlighted in Oral Presentation at ESMO Congress; On Track to Advance into Phase 1 Expansion in 2H 2021
On Track to Initiate SELECT-AML-1 Randomized Phase 2 Trial of Tamibarotene in AML and Dose Confirmation Study for SY-2101 in APL in 2H 2021
Management to Host Conference Call at 8:30 a.m. ET Today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals... More
